Gyongyi Szabo
Experienced in Crohn's Disease

Dr. Gyongyi Szabo

Internal Medicine
110 Francis Street, Suite 8E, 
Boston, MA 
On Staff At
37 Years of Experience
Experienced in Crohn's Disease
110 Francis Street, Suite 8E, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gyongyi Szabo is an Internal Medicine provider in Boston, Massachusetts. Dr. Szabo has been practicing medicine for over 37 years and is rated as an Experienced provider by MediFind in the treatment of Crohn's Disease. Her top areas of expertise are Hepatitis, Non-Alcoholic Fatty Liver Disease, Liver Failure, Liver Transplant, and Colonoscopy.

Her clinical research consists of co-authoring 256 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Debrecen Medical University
Residency
UMass Memorial Medical Center
Specialties
Internal Medicine
Licenses
Internal Medicine in MA
Fellowships
Leopold Franzens Univ Innsbruck
Rijksuniversiteit Te Leiden
UMass Memorial Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

BIDMC - Division of Gastroenterology/Liver Center
110 Francis Street, Suite 8E, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

255 Total Publications

Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Journal: Nature reviews. Gastroenterology & hepatology
Published: August 28, 2025
Similar Doctors
Adam S. Cheifetz
Elite in Crohn's Disease
Dr. Adam S. Cheifetz
Internal Medicine
Elite in Crohn's Disease
Dr. Adam S. Cheifetz
Internal Medicine

Beth Israel Deaconess Healthcare - Chestnut Hill

200 Boylston Street, Floor 4 Gastroenterology, 
Chestnut Hill, MA 
 (3.9 miles away)
617-754-8888
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Cheifetz is an Internal Medicine provider in Chestnut Hill, Massachusetts. Dr. Cheifetz is rated as a Distinguished provider by MediFind in the treatment of Crohn's Disease. His top areas of expertise are Crohn's Disease, Ulcerative Colitis, Viral Gastroenteritis, Colonoscopy, and Endoscopy.

Joseph D. Feuerstein
Elite in Crohn's Disease
Dr. Joseph D. Feuerstein
Internal Medicine
Elite in Crohn's Disease
Dr. Joseph D. Feuerstein
Internal Medicine

BIDMC Endoscopy - West Campus

185 Pilgrim Road, Farr 1, WPC, 
Boston, MA 
 (0.3 miles away)
617-754-8888
Languages Spoken:
English, Hebrew
See accepted insurances
Offers Telehealth

Joseph Feuerstein is an Internal Medicine provider in Boston, Massachusetts. Dr. Feuerstein is rated as an Elite provider by MediFind in the treatment of Crohn's Disease. His top areas of expertise are Gastrointestinal Bleeding, Ulcerative Colitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy.

Distinguished in Crohn's Disease
Dr. Vijay Yajnik
Internal Medicine
Distinguished in Crohn's Disease
Dr. Vijay Yajnik
Internal Medicine
55 Fruit St Blk 4, Gastroenterology Associates, 
Boston, MA 
 (2.5 miles away)
617-724-6005
Languages Spoken:
English
See accepted insurances

Vijay Yajnik is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Yajnik is rated as a Distinguished provider by MediFind in the treatment of Crohn's Disease. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Ulcerative Colitis, Endoscopy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Szabo's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile